Bristol-Myers Squibb, ConcertAI team up on real-world data, artificial intelligence

Boston-based ConcertAI and Bristol-Myers Squibb have formed a partnership to integrate various data sources and apply AI and machine learning in clinical trials, protocol design and the generation of insights for precision treatment and improved patient outcomes. Under the deal, BMS will use ConcertAI’s eurekaHealth real-world data and AI insights system. The idea, they said, is to accelerate insights through novel health economic outcomes and also synthetic control arm studies in clinical development.

Read More